QQ客服 官方微博 反馈留言

	Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
	Fei Long; Ye He; Haoyu Fu; Yun Li; Xubin Bao; Quanren Wang; Yigang Wang; Chengying Xie; Liguang Lou
刊名	Cancer science
	2019
关键词	CDK 4/6 SHR6390 breast cancer drug resistance palbociclib
ISSN号	1349-7006
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4736816
专题	湖南大学
作者单位	Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci-Tech University, Zhejiang, 310018, China. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. University of Chinese Academy of Sciences, Beijing, 100049, China.
推荐引用方式 GB/T 7714	Fei Long,Ye He,Haoyu Fu,et al. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.[J]. Cancer science,2019.
APA	Fei Long.,Ye He.,Haoyu Fu.,Yun Li.,Xubin Bao.,...&Liguang Lou.(2019).Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models..Cancer science.
MLA	Fei Long,et al."Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.".Cancer science (2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。